The stock of Xeris Biopharma Holdings Inc (NASDAQ: XERS) has increased by 12.74 when compared to last closing price of 1.57. Despite this, the company has experienced a 5.04% gain in its stock price over the last five trading sessions. PennyStocks reported 2023-11-17 that Ever wonder what signals to look for in the stock market today? Let’s talk about insider buying – a goldmine of clues that could lead you to the next prospect to add to your list of penny stocks to watch.
Is It Worth Investing in Xeris Biopharma Holdings Inc (NASDAQ: XERS) Right Now?
The 36-month beta value for XERS is also noteworthy at 1.39. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average price estimated by analysts for XERS is $4.60, which is $2.83 above than the current price. The public float for XERS is 129.56M, and at present, short sellers hold a 6.02% of that float. The average trading volume of XERS on November 20, 2023 was 1.04M shares.
XERS’s Market Performance
XERS’s stock has seen a 5.04% increase for the week, with a 2.31% rise in the past month and a -25.94% fall in the past quarter. The volatility ratio for the week is 13.52%, and the volatility levels for the past 30 days are at 9.91% for Xeris Biopharma Holdings Inc The simple moving average for the past 20 days is 1.83% for XERS’s stock, with a -14.48% simple moving average for the past 200 days.
Analysts’ Opinion of XERS
Many brokerage firms have already submitted their reports for XERS stocks, with Craig Hallum repeating the rating for XERS by listing it as a “Buy.” The predicted price for XERS in the upcoming period, according to Craig Hallum is $4.50 based on the research report published on August 28, 2023 of the current year 2023.
XERS Trading at -1.61% from the 50-Day Moving Average
After a stumble in the market that brought XERS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.35% of loss for the given period.
Volatility was left at 9.91%, however, over the last 30 days, the volatility rate increased by 13.52%, as shares surge +1.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.71% lower at present.
During the last 5 trading sessions, XERS rose by +5.04%, which changed the moving average for the period of 200-days by +40.48% in comparison to the 20-day moving average, which settled at $1.7398. In addition, Xeris Biopharma Holdings Inc saw 33.08% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at XERS starting from Shannon John Patrick Jr, who purchase 30,769 shares at the price of $1.64 back on Nov 17. After this action, Shannon John Patrick Jr now owns 1,408,575 shares of Xeris Biopharma Holdings Inc, valued at $50,400 using the latest closing price.
Schmid John P., the Director of Xeris Biopharma Holdings Inc, purchase 6,500 shares at $1.51 during a trade that took place back on Nov 16, which means that Schmid John P. is holding 6,500 shares at $9,815 based on the most recent closing price.
Stock Fundamentals for XERS
Current profitability levels for the company are sitting at:
- -72.97 for the present operating margin
- +69.63 for the gross margin
The net margin for Xeris Biopharma Holdings Inc stands at -85.86. The total capital return value is set at -37.72, while invested capital returns managed to touch -44.55. Equity return is now at value -209.81, with -19.59 for asset returns.
Based on Xeris Biopharma Holdings Inc (XERS), the company’s capital structure generated 438.31 points at debt to equity in total, while total debt to capital is 81.42. Total debt to assets is 57.47, with long-term debt to equity ratio resting at 434.81. Finally, the long-term debt to capital ratio is 80.77.
When we switch over and look at the enterprise to sales, we see a ratio of 2.10, with the company’s debt to enterprise value settled at 0.77. The receivables turnover for the company is 4.57 and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.54.
In summary, Xeris Biopharma Holdings Inc (XERS) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.